Get the Stockscreener App
0.6502
5.59%
-0.0384
Harvard Bioscience Inc stock is traded at $0.6502, with a volume of 132.67K.
It is down -5.59% in the last 24 hours and down -44.91% over the past month.
Harvard Bioscience Inc is a developer, manufacturer, and seller of technologies, specialized products and services that enable fundamental research, discovery, and pre-clinical testing for drug development. Its primary focus is scientific instruments used to advance life sciences and research. With operations in North America, Europe and china it sells through a combination of direct and distribution channels to customers around the world. The product brands of the company include Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab.. The majority of its revenue comes from the United States.
See More
Previous Close:
$0.6886
Open:
$0.6863
24h Volume:
132.67K
Relative Volume:
0.46
Market Cap:
$29.23M
Revenue:
$106.79M
Net Income/Loss:
$-8.73M
P/E Ratio:
-3.251
EPS:
-0.2
Net Cash Flow:
$10.81M
1W Performance:
+1.56%
1M Performance:
-44.91%
6M Performance:
-76.36%
1Y Performance:
-85.22%
1-Day Range:
$0.65
$0.7173
1-Week Range:
$0.602
$0.73
52-Week Range:
$0.602
$4.70
Harvard Bioscience Inc Stock (HBIO) Company Profile
Name
Harvard Bioscience Inc
Sector
Industry
Phone
(508) 893-8999
Address
84 OCTOBER HILL RD, HOLLISTON, MA
Compare HBIO with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
HBIO
Harvard Bioscience Inc
|
0.6501 | 29.23M | 106.79M | -8.73M | 10.81M | -0.20 |
|
ISRG
Intuitive Surgical Inc
|
493.76 | 176.29B | 8.35B | 2.32B | 1.30B | 6.41 |
|
BDX
Becton Dickinson Co
|
231.19 | 66.56B | 20.64B | 1.73B | 2.94B | 6.02 |
|
ALC
Alcon Inc
|
91.49 | 44.95B | 9.91B | 1.02B | 665.00M | 2.05 |
|
RMD
Resmed Inc
|
222.00 | 32.81B | 4.93B | 1.25B | 1.38B | 8.47 |
|
BAX
Baxter International Inc
|
33.81 | 17.41B | 17.28B | 108.00M | 391.00M | 0.20 |
Harvard Bioscience Inc Stock (HBIO) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-10-23 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Jan-07-21 | Upgrade | The Benchmark Company | Speculative Buy → Buy |
| Dec-09-20 | Initiated | Northland Capital | Outperform |
| Nov-10-20 | Initiated | KeyBanc Capital Markets | Overweight |
| Jul-08-19 | Downgrade | Janney | Buy → Neutral |
| Jan-24-18 | Reiterated | Janney | Buy |
| Jan-23-18 | Reiterated | The Benchmark Company | Buy |
| Nov-17-16 | Initiated | Singular Research | Buy |
| Jul-28-15 | Initiated | The Benchmark Company | Buy |
View All
Harvard Bioscience Inc Stock (HBIO) Latest News
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges By Investing.com - Investing.com South Africa
Harvard Bioscience at 37th Annual ROTH Conference: Strategic Growth Amid Challenges - Investing.com
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q4 2024 Earnings Call Transcript - Insider Monkey
Harvard Bioscience Full Year 2024 Earnings: EPS Beats Expectations - Yahoo Finance
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: - GuruFocus.com
Harvard Bioscience Inc (HBIO) Q4 2024 Earnings Call Highlights: Navigating Challenges with ... By GuruFocus - Investing.com Canada
Harvard Bioscience Reports 2024 Financial Results - TipRanks
Harvard Bioscience Navigates Growth Amid Challenges - TipRanks
Harvard Bioscience secures waiver for credit covenant By Investing.com - Investing.com Australia
Harvard Bioscience, Inc. to Participate in Two Investor Conferences in March 2025 - GlobeNewswire
Harvard Bioscience CEO to Host Fireside Chats at Roth and KeyBanc Healthcare Forums - StockTitan
Harvard Bioscience Announces Fourth Quarter and Full-Year 2024 Financial Results - GlobeNewswire
Earnings call transcript: Harvard Bioscience Q4 2024 beats expectations but faces market challenges - Investing.com
Harvard Bioscience Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Harvard Bioscience slumps after weak revenue forecast - TradingView
HARVARD BIOSCIENCE Earnings Results: $HBIO Reports Quarterly Earnings - Nasdaq
Harvard Bioscience reports Q4 adjusted EPS 6c vs. 4c last year - TipRanks
Harvard Bioscience earnings beat, revenue topped estimates By Investing.com - Investing.com UK
Harvard Bioscience Achieves Profit Turnaround Despite Revenue Challenges in Latest Quarter - StockTitan
Harvard Bioscience IncQ4 2024 Revenues $24.6 Million -March 12, 2025 at 07:04 am EDT - Marketscreener.com
Harvard Bioscience Q4 and Full-Year 2024 Financial Results - TradingView
Harvard Bioscience secures waiver for credit covenant - Investing.com
Harvard BioscienceExploring Alternative Capital Sources For Refinancing Outstanding Indebtedness By June 30 - Marketscreener.com
Costco Price Plunge Equals Opportunity for Investors - The Globe and Mail
Harvard Bioscience (HBIO) Expected to Announce Earnings on Wednesday - Armenian Reporter
Harvard Bioscience, Inc. to Host Earnings Call - ACCESS Newswire
HBIO stock touches 52-week low at $0.86 amid market challenges - Investing.com Australia
BioAtla Inc (BCAB) shows promising results - US Post News
Dycom Industries, Inc. to Participate in Upcoming Investor Conferences - The Manila Times
Harvard Bioscience to Showcase Latest Solutions for - GlobeNewswire
Can These New Research Platforms Transform Toxicology Studies? Harvard Bioscience Reveals Latest Innovations - StockTitan
Harvard Bioscience Schedules Fourth Quarter 2024 Earnings Conference Call for March 12, 2025 at 8:00 AM ET - The Manila Times
Harvard Bioscience, Inc. to Announce Q4 2024 Financial Results on March 12, 2025 - Nasdaq
How to Access Harvard Bioscience's Critical Q4 2024 Financial Results Call - StockTitan
5 Top AI Stocks I'm Buying on the Dip - The Globe and Mail
Harvard Bioscience, Inc. (NASDAQ:HBIO) Q3 2024 Earnings Call Transcript - MSN
NAYA Biosciences Announces Nomination of New Board Members - The Manila Times
Harvard Bioscience stock hits 52-week low at $1.23 By Investing.com - Investing.com Canada
BostInno✈️ Net-zero aviation fuel | MassVentures' deep tech investments - The Business Journals
HBIO stock touches 52-week low at $1.3 amid sharp annual decline - Investing.com Australia
Preclinical Software for Physiology DA and AS Market to Grow by USD 4.38 Billion from 2025-2029, Driven by Bioinformatics Tools in Research, AI-Powered Market EvolutionTechnavio - The Malaysian Reserve
Electroporation Instruments Market Growth 2025: Key Industry Trends, Share and Demand by 2033 - WICZ
Harvard Bioscience Inc (HBIO) Stock Sees a-10.84 Decrease - The News Heater
OceanFirst Financial Corp (OCFC) vs. Its Peers: A Comparison - The News Heater
Why Investors Shouldn't Be Surprised By Harvard Bioscience, Inc.'s (NASDAQ:HBIO) 31% Share Price Plunge - Simply Wall St
Harvard Bioscience, Inc. (NASDAQ:HBIO) Looks Inexpensive After Falling 31% But Perhaps Not Attractive Enough - Simply Wall St
JPMorgan Chase & Co. Makes New $75,000 Investment in WEBTOON Entertainment Inc. (NASDAQ:WBTN) - Defense World
JPMorgan Chase & Co. Boosts Stock Holdings in Harvard Bioscience, Inc. (NASDAQ:HBIO) - Defense World
HBIO stock touches 52-week low at $1.7 amid market challenges - Investing.com India
Pre-market Movers: SLGL, VIRX, ANVS, CUTR... - RTTNews
Harvard Bioscience, Inc. (NASDAQ:HBIO) Short Interest Up 22.8% in January - MarketBeat
Harvard Bioscience Inc Stock (HBIO) Financials Data
Revenue
Net Income
Cash Flow
EPS
Harvard Bioscience Inc Stock (HBIO) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Green James W | Chief Executive Officer |
Jun 06 '24 |
Buy |
3.07 |
20,000 |
61,400 |
3,101,091 |
1.12%
0.04%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):